| Field | Specification |
|---|---|
| Target | |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C28H27F4N7O3S |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
LY-2584702 tosylate salt selectively and competitively inhibits p70S6K at the ATP-binding site, with an IC50 of 4 nM. In an S6K1 enzyme assay, it showed an IC50 of 2 nM. It is supplied as a light yellow to yellow solid (C28H27F4N7O3S, MW 617.62) at 99.50% purity.
Physical & Chemical Properties
| CAS Number | 1082949-68-5 |
|---|---|
| Molecular Formula | C28H27F4N7O3S |
| Molecular Weight | 617.62 g/mol |
| Purity | 99.50% |
| Appearance | Solid |
| Color | Light yellow to yellow |
| SMILES | CN1C=C(C2=CC=C(F)C(C(F)(F)F)=C2)N=C1C3CCN(C4=C5C(NN=C5)=NC=N4)CC3.O=S(C6=CC=C(C)C=C6)(O)=O |
| Target | p70S6K |
| Signaling Pathway | MAPK/ERK Pathway |
| Solubility | In Vitro: DMSO: 10.25 mg/mL (16.60 mM; Requires sonication and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | 4°C, sealed storage, away from moisture. In solvent: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target
[1][2]
|
p70S6K 4 nM (IC50) |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 10.25 mg/mL (16.60 mM) | requires sonication and warming; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 1 year) or -20°C (up to 6 months); sealed storage, away from moisture; avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 1 mg/mL (1.62 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 1 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (10.0 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | 1 mg/mL (1.62 mM); suspension; requires sonication |
| How to prepare | Gives a suspension at 1 mg/mL. The suspension is suitable for oral and intraperitoneal dosing. For 1 mL of working solution: add 100 μL DMSO stock (10.0 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Protocol 3
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 1 mg/mL (1.62 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 1 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (10.0 mg/mL) to 900 μL corn oil. |
Data provided by the manufacturer.
In Vitro
In HCT116 colon cancer cells, LY-2584702 (LY2584702) reduces phosphorylation of the S6 ribosomal protein (pS6), with an IC50 of 0.1-0.24 μM[1]. In an S6K1 enzyme assay, LY-2584702 (LY2584702) has an IC50 of 2 nM, and for pS6 inhibition in cells the IC50=100 nM. At high concentrations, LY-2584702 shows some activity against the S6K-related kinases MSK2 and RSK (enzyme assay IC50=58-176 nM). In EOMA cells, LY-2584702 inhibits S6K activity in a dose-dependent manner, as measured by phosphorylation of its downstream effector S6[2]. LY-2584702 (LY2584702) significantly inhibits A549 proliferation after treatment for over 24 h at 0.1 μM (P<0.05), and the decline becomes more pronounced with longer treatment and/or higher drug concentration (all P<0.05). SK-MES-1 gives similar results, although clear inhibition by LY-2584702 appears only at 0.6 μM (P<0.05), much higher than for A549[3].
In Vivo
In U87MG glioblastoma and HCT116 colon carcinoma xenograft models alike, LY-2584702 demonstrates significant single-agent efficacy at two dose levels, 2.5 mg/kg twice daily (BID) and 12.5 mg/kg BID. At TMED50 (threshold minimum effective dose 50%) (2.3 mg/kg) and TMED90 (10 mg/kg), LY-2584702 achieves statistically significant tumor growth reduction in the HCT116 colon carcinoma xenograft model[1]. To probe S6K function in vivo, shAkt3-expressing EOMA cells are implanted in nu/nu mice and then treated for 14 days with LY-2584702 or Rapamycin. Tumors removed after 14 days show that LY-2584702 inhibits S6 phosphorylation almost as effectively as Rapamycin. Compared with pLKO, loss of Akt3 increases tumor growth. LY-2584702 alone does not significantly affect the growth of pLKO tumors, but LY-2584702 significantly reduces the growth of tumors with shAkt3[2].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Cell Assay[3]
Dissolve LY-2584702 fully in 20 mL 10% DMSO and store at -80°C. For in vitro experiments, dilute LY-2584702 further in 0.5% Tween 80, 5% propylene glycol, and 30% PEG400 to reach the following DMSO concentrations: 0.1 μM, 0.2 μM, 0.6 μM, and 1.0 μM. Measure cell proliferation in vitro with Cell Counting Kit-8 (CCK-8). Treat cell lines A549 and SK-MES-1 with LY-2584702 at the different concentrations for 24 h, then seed in 96-well plates at 5×103 per well, with six repeats. Use DMSO-treated cells, i.e., LY-2584702 at 0, as the negative control. Read cell absorbance at 450 nm every 24 h after seeding to assess proliferative activity[3].
Animal Administration[2]
Mice[2] Prepare LY-2584702 in 0.25% Tween-80 and 0.05% antifoam and give orally to mice (12.5 mg/kg twice daily). Inject EOMA cells (0.3×106) subcutaneously into 6- to 8-week-old nu/nu female mice (2 sites/mouse, 4-5 mice/group). Measure tumor size daily. For drug treatment, once tumors reach 0.01 cm3, treat the animals with vehicle control or LY-2584702 (12.5 mg/kg twice daily, oral dosing). Afterward, measure tumor size every 3 to 4 days[2].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
The chemokine CCL1 triggers an AMFR-SPRY1 pathway that promotes differentiation of lung fibroblasts into myofibroblasts and drives pulmonary fibrosis. Immunity 2021 Sep 14;54(9):2042-2056.e8. PMID: 34407391
Interleukin-33 facilitates liver regeneration through serotonin-involved gut-liver axis. Hepatology 2023 May 1;77(5):1580-1592. PMID: 36129070
Overcoming resistance to EGFR monotherapy in HNSCC by identification and inhibition of individualized cancer processes. Theranostics 2022 Jan 1;12(3):1204-1219.
Dihydroartemisinin ameliorates retinal vascular dysfunction in diabetes mellitus via the FASN/Kmal-mTOR/SREBP1 feedback loop. Pharmacol Res 2021 Oct 4;105871. PMID: 34619345
Vitamin B6 preserves the stemness-like phenotypes and antitumor ability of CD8+ T cells. Dev Cell 2025 Nov 27:S1534-5807(25)00691-4. PMID: 41314217
MELK inhibits cuproptosis in diffuse large B-cell lymphoma cells via the PI3K/mTOR/S6K-DLAT signaling axis. Mol Cell Biochem 2026 Jun 2. PMID: 42228272
